Accelerating Cancer Drug Development

Accelerating Cancer Drug Development -From target to patients, BioNow will be hosting this event at Alderley Park on the 27th of February 2018. Focusing upon the strengths in the discovery, development and manufacture of cancer medicines in the North of England through to commercialisation (patients), this event will highlight industry, academic and clinical strengths whilst [...]

By |2018-07-11T11:58:57+00:00February 27th, 2018|Events|Comments Off on Accelerating Cancer Drug Development

Collaboration and Competition: Ethics in Toxicology

Two of the biggest ethical challenges in pharmaceutical toxicology are the use of animals in testing and the high safety-related attrition rates in new drug development.  Yet very little is invested in these two fields compared with investment in new efficacy models, new disease targets and new technologies.  How can this be addressed?  In this [...]

By |2018-05-30T16:00:00+00:00February 9th, 2018|Toxicology, Publications|Comments Off on Collaboration and Competition: Ethics in Toxicology

New Drug Discovery Alliance to Tackle High Rate of Failure

Two prominent preclinical safety companies have launched a unique European alliance to address the high safety-related failure rate in drug development. This alliance will provide both high-throughput ion channel screening, advanced cardiovascular safety testing models and experienced project scientists in one collaborative team. This enables both large and small pharmaceutical companies to make the right [...]

By |2018-06-27T16:34:31+00:00September 20th, 2017|Press|Comments Off on New Drug Discovery Alliance to Tackle High Rate of Failure

APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.  

In February, APTrans signed a service agreement with Evgen Pharma to provide support to their lead program, SFX-01. Evgen Pharma is a clinical stage drug development company with projects in breast cancer and subarachnoid haemorrhage. APTrans is a consortium of companies based at the BioHub at Alderley Park, formed by ApconiX, Aptus Clinical and Seda [...]

By |2018-07-11T16:56:25+00:00March 8th, 2017|Press|Comments Off on APTrans signs agreement with Evgen Pharma to support the development of the lead product, SFX-01.